Healthcare Industry News: AIGISRx
News Release - March 31, 2009
TYRX Announces the Appointment of George D. Landau as Vice President, Business DevelopmentMONMOUTH, NJ--(Healthcare Sales & Marketing Network)--Mar 31, 2009 -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, today announced that it has appointed George D. Landau as Vice President, Business Development.
Mr. Landau brings over 18 years of experience for business strategy and planning, acquisitions, licensing, strategic partnerships and equity investment opportunities in the medical device industry to TYRX. Most recently as Vice President, Business Development and Marketing Planning and member of the Senior Management Team at Tengion, Inc., a privately held company focusing on the emerging field of Regenerative Medicine, Mr. Landau led the development of partnership initiatives and pre-commercialization planning for a novel product using combination biologic/medical device technology. Prior to Tengion, Mr. Landau was with Cordis Corporation, Johnson & Johnson's interventional cardiology franchise, where he served as Executive Director, New Business Development. At Cordis, Mr. Landau facilitated the creation of the Cypher drug eluting stent franchise, and endovascular business unit. Mr. Landau led the licensing efforts of Sirolimus from Wyeth and collaborations and licenses for polymer drug delivery technology as well as other strategic efforts including the acquisition of Nitinol Devices and Components (NDC), and the acquisition of Teramed, Inc. Prior to Johnson & Johnson, Mr. Landau held positions of increasing responsibility in business development at Pfizer Inc. where he led and supported numerous strategic initiatives as well as acquisitions and divestures in the medical fields of General and Cardiac Surgery, Interventional Cardiology and Radiology, Urology, Cancer and Pain Management. Mr. Landau received his B.A. in Economics from Tulane University and his M.B.A. from New York University.
"George brings to TYRX a business development capability uniquely suited to our growing presence in implantable combination drug/device products," remarked William Edelman, President and CEO for TYRX. Mr. Edelman continued, "George's clear track record of building successful, value creating transactions will accelerate our trajectory as an innovative leader in the medical device industry."
Mr. Landau remarked, "I am thrilled to join TYRX to help shape the business development strategy and advance efforts to build-out partnerships and new opportunities. One of the most exciting areas for TYRX is its strong technology platform and potential for applications in a broad spectrum of clinical applications. I look forward to working with an impressive team focused on development and commercialization of products addressing important clinical needs."
About TYRX, Inc.
TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products, including the AIGISRx(TM) Anti-Bacterial Envelope. AIGISRx contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm device related endocarditis, including "superbugs" or MRSA. In addition, AIGISRx is intended to securely hold a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. Following commercial release in June 2008, AIGISRx has been implanted in over 2,500 patients nationwide. In February 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space.
For more information, please visit www.TYRX.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.